Bi-level Positive Airway Pressure Devices (BiPAP) Market Overview:
The Bi-level Positive Airway Pressure Devices (BiPAP) Market was valued at US$ 1.45 Billion in 2024 and is anticipated to reach US$ 3.70 Billion by 2033, at a CAGR of 0.055 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Bi-level Positive Airway Pressure Devices (BiPAP) Market.

This report delivers a comprehensive overview of the Bi-level Positive Airway Pressure Devices (BiPAP) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bi-level Positive Airway Pressure Devices (BiPAP) Market. The Bi-level Positive Airway Pressure Devices (BiPAP) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Bi-level Positive Airway Pressure Devices (BiPAP) Market Scope:
By Product
• Devices
• Masks
• Aftermarket Parts and Accessories

By Indication
• Obstructive Sleep Apnea
• Central Sleep Apnea
• Complex Sleep Apnea
• Chronic Obstructive Pulmonary Disease (COPD)
• Acute Respiratory Failure
• Chronic Respiratory Failure
• Neuromuscular Disorders
• Obesity Hypoventilation Syndrome
• Pneumonia and Other Respiratory Infections
• Post-operative Respiratory Support
• Others

By Technology
• Integrated Humidification
• Heated Tubing
• Smart Connectivity
• Bluetooth-enabled Devices
• Wi-Fi-enabled Devices
• Cloud-based Monitoring
• Telemonitoring Compatible Devices
• Noise Reduction Technology
• Pressure Relief Technology
• Leak Compensation Systems
• Touchscreen / Digital Interface
• Others

By Portability
• Stationary Devices
• Portable Devices
• Travel-friendly Devices
• Others

By Patient Type
• Adult
• Pediatric
• Geriatric

By End-User
• Hospitals
• Academic / Teaching Hospitals
• Sleep Clinics and Sleep Laboratories
• Home Healthcare Settings
• Ambulatory Surgical Centers
• Long-term Care Facilities
• Rehabilitation Centers
• Others

Key Players
• Pfizer, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• GlaxoSmithKline plc
• H. Lundbeck A/S
• Johnson & Johnson
• Bristol-Myers Squibb Company
• BioXcel Therapeutics, Inc.
• Impel Pharmaceuticals Inc.
• Lee Pharma Limited
• Teva Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals LLC
• AbbVie Inc.
• Aurobindo Pharma Limited
• Apotex Inc.
• F. Hoffmann-La Roche Ltd.
• Hikma Pharmaceuticals PLC
• Axsome Therapeutics, Inc.
• Alkermes plc
• Alexza Pharmaceuticals, Inc.

Major Highlights
This report delivers a comprehensive overview of the Bi-level Positive Airway Pressure Devices (BiPAP) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bi-level Positive Airway Pressure Devices (BiPAP) Market. The Bi-level Positive Airway Pressure Devices (BiPAP) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
✓ Increase Your Customer Base by 3X using our Partner Identification tool
✓ Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
✓ Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
✓ Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Definition and Overview
1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period
2. Executive Summary
2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising prevalence of psychiatric disorders and substance-induced agitation
3.1.1.2. Increasing emergency department visits related to acute behavioral disturbances
3.1.1.3. Growing adoption of rapid-acting and novel drug delivery formulations
3.1.2. Restraints
3.1.2.1. Safety concerns and adverse effects associated with antipsychotics and sedatives
3.1.2.2. Stringent regulatory scrutiny and post-marketing safety requirements
3.1.3. Opportunity
3.1.3.1. Development of non-invasive and fast-acting delivery systems (inhaled, intranasal, sublingual)
3.1.3.2. Increasing demand in emerging markets due to improving psychiatric care access
3.1.3.3. Pipeline development targeting agitation in dementia and Alzheimer’s disease
3.1.4. Trends
3.1.4.1. Shift toward atypical antipsychotics with improved safety profiles
3.1.4.2. Increasing preference for rapid-onset formulations in emergency psychiatry
3.1.5. Impact Analysis
4. Industry Analysis
4.1. Porter’s Five Force Analysis – Global Bi-level Positive Airway Pressure Devices (BiPAP)
4.2. Geopolitical & Supply Chain Exposure
4.2.1. API Sourcing Concentration for Antipsychotics and Benzodiazepines
4.2.2. Trade Policies, Export Controls, and Psychiatric Drug Supply Risks
4.3. Social & Patient-Centric Factors
4.3.1. Physician Prescribing Behavior in Emergency Psychiatry and Acute Care
4.3.2. Brand Preference vs Generic Substitution Across Antipsychotics and Sedatives
4.3.3. Patient and Caregiver Concerns Regarding Sedation, Safety, and Monitoring
4.3.4. Awareness Gaps in Early Recognition and Management of Acute Agitation
4.4. Economic Factors
4.4.1. Reimbursement and Coverage in Hospital and Emergency Care Settings
4.4.2. Inflationary Pressure on APIs, Sterile Injectables, and CNS Drug Manufacturing
4.4.3. Currency Volatility Impacting Export-Oriented CNS Drug Manufacturers
4.5. Pricing Analysis
4.6. Regulatory Analysis
4.7. Go-To-Market (GTM) Strategy
4.8. Innovation & R&D Trends
4.9. Sustainability and ESG Analysis
4.10. Acute Agitation Treatment Ecosystem Participants
4.11. Buyer Decision Criteria & Adoption Drivers
4.12. DMI Opinion – Strategic Outlook for the Global Bi-level Positive Airway Pressure Devices (BiPAP) Market
5. By Product
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
5.1.2. Market Attractiveness Index, By Product
5.2. Devices*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Fixed Pressure BiPAP Devices
5.2.4. Auto-adjusting BiPAP Devices
5.2.5. BiPAP ST (Spontaneous/Timed) Devices
5.2.6. BiPAP AVAPS Devices
5.2.7. Portable / Travel BiPAP Devices
5.2.8. ICU / Critical Care BiPAP Systems
5.2.9. Pediatric / Neonatal BiPAP Devices
5.2.10. Others
5.3. Masks
5.3.1. Full Face Masks
5.3.2. Nasal Masks
5.3.3. Nasal Pillow Masks
5.3.4. Total Face Masks
5.3.5. Pediatric Masks
5.3.6. Others
5.4. Aftermarket Parts and Accessories
5.4.1. Tubing / Breathing Circuits
5.4.2. Humidifiers
5.4.3. Filters
5.4.4. Headgear and Straps
5.4.5. Cushions and Mask Liners
5.4.6. Water Chambers
5.4.7. Batteries and Power Adapters
5.4.8. Carrying Cases
5.4.9. Others
6. By Indication
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Obstructive Sleep Apnea*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Central Sleep Apnea
6.4. Complex Sleep Apnea
6.5. Chronic Obstructive Pulmonary Disease (COPD)
6.6. Acute Respiratory Failure
6.7. Chronic Respiratory Failure
6.8. Neuromuscular Disorders
6.9. Obesity Hypoventilation Syndrome
6.10. Pneumonia and Other Respiratory Infections
6.11. Post-operative Respiratory Support
6.12. Others
7. By Technology
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. Integrated Humidification*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Heated Tubing
7.4. Smart Connectivity
7.5. Bluetooth-enabled Devices
7.6. Wi-Fi-enabled Devices
7.7. Cloud-based Monitoring
7.8. Telemonitoring Compatible Devices
7.9. Noise Reduction Technology
7.10. Pressure Relief Technology
7.11. Leak Compensation Systems
7.12. Touchscreen / Digital Interface
7.13. Others
8. By Portability
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
8.1.2. Market Attractiveness Index, By Portability
8.2. Stationary Devices*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Portable Devices
8.4. Travel-friendly Devices
8.5. Others
9. By Patient Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.1.2. Market Attractiveness Index, By Patient Type
9.2. Adult*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pediatric
9.4. Geriatric
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Academic / Teaching Hospitals
10.4. Sleep Clinics and Sleep Laboratories
10.5. Home Healthcare Settings
10.6. Ambulatory Surgical Centers
10.7. Long-term Care Facilities
10.8. Rehabilitation Centers
10.9. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.9.1. US
11.2.9.2. Canada
11.2.9.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.9.1. Germany
11.3.9.2. UK
11.3.9.3. France
11.3.9.4. Russia
11.3.9.5. Italy
11.3.9.6. Spain
11.3.9.7. Norway
11.3.9.8. Netherlands
11.3.9.9. Sweden
11.3.9.10. Denmark
11.3.9.11. Belgium
11.3.9.12. Switzerland
11.3.9.13. Austria
11.3.9.14. Poland
11.3.9.15. Finland
11.3.9.16. Rest of Europe
11.4. Latin America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.9.1. Brazil
11.4.9.2. Argentina
11.4.9.3. Rest of Latin America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.9.1. China
11.5.9.2. India
11.5.9.3. Japan
11.5.9.4. Australia
11.5.9.5. South Korea
11.5.9.6. New Zealand
11.5.9.7. Indonesia
11.5.9.8. Malaysia
11.5.9.9. Philippines
11.5.9.10. Singapore
11.5.9.11. Thailand
11.5.9.12. Vietnam
11.5.9.13. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.6.9.1. UAE
11.6.9.2. Saudi Arabia
11.6.9.3. South Africa
11.6.9.4. Israel
11.6.9.5. Egypt
11.6.9.6. Turkey
11.6.9.7. Qatar
11.6.9.8. Kuwait
11.6.9.9. Oman
11.6.9.10. Bahrain
11.6.9.11. Rest of Middle East and Africa
12. Competitive Landscape Analysis
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
12.4. Partner Identification Analysis
12.5. Investment & Funding Landscape
12.6. Strategic Alliances & Innovation Pipelines
13. Company Profiles
13.1. Pfizer, Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.3. Revenue Analysis
13.1.4. Pricing Analysis
13.1.5. SWOT Analysis
13.1.6. Recent Developments
13.1.6.1. Major Deals
13.1.6.2. M&A
13.1.6.3. Collaboration
13.1.6.4. Acquisition
13.1.6.5. Joint Ventures
13.1.6.6. Innovations
13.1.7. Recent News
13.1.7.1. Events
13.1.7.2. Conferences
13.1.7.3. Symposiums
13.1.7.4. Webinars
13.2. Otsuka Pharmaceutical Co., Ltd.
13.3. GlaxoSmithKline plc
13.4. H. Lundbeck A/S
13.5. Johnson & Johnson
13.6. Bristol-Myers Squibb Company
13.7. BioXcel Therapeutics, Inc.
13.8. Impel Pharmaceuticals Inc.
13.9. Lee Pharma Limited
13.10. Teva Pharmaceutical Industries Ltd.
13.11. Amneal Pharmaceuticals LLC
13.12. AbbVie Inc.
13.13. Aurobindo Pharma Limited
13.14. Apotex Inc.
13.15. F. Hoffmann-La Roche Ltd.
13.16. Hikma Pharmaceuticals PLC
13.17. Axsome Therapeutics, Inc.
13.18. Alkermes plc
13.19. Alexza Pharmaceuticals, Inc. (LIST NOT EXHAUSTIVE )
14. Global Bi-Level Positive Airway Pressure Devices (BiPAP) Market – Research Methodology
14.1. Research Data
14.1.1. Secondary Data
14.1.2. Primary Data
14.1.3. CAGR Analysis
14.2. Market Size Estimation Methodology
14.2.1. Bottom-Up Approach
14.2.2. Top-Down Approach
14.3. Market Breakdown & Data Triangulation
14.4. Research Assumptions
14.5. Limitations
15. Appendix
15.1. About Us and Services
15.2. Contact Us